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Abstract. We have previously reported that deletion of the
retinoblastoma gene Rb leads to rapid but transient p53
stabilisation. We investigated here the pathways involved. We
show that upon Rb-deletion dysregulated E2F activates p19ARF
expression that localises in the nucleoli. There it interacts
with MDM2, leading to P53 stabilisation. At the same time,
ATR is activated, activating CHK1 that may phosphorylate
P53 but also contribute to inhibition of MnSOD expression
leading to accumulation of ROS (reactive oxygen species) and
subsequent DNA injury, which in turn maintains ATR/CHK1
activated. However, from 72 h after Rb deletion, NPM interacts
with P19ARF and concomitantly the interaction between
p19ARF and MDM2 decreases leading to a return to P53
degradation. This occurs despite the persistence of the
DNA damage response pathways. We therefore observe in
primary cells not subjected to exogenous gene expression
or exogenous DNA damaging treatment, activation of 2
concomitant pathways of activation of P53 that are dealt with
in independent manner: an oncogenic pathway with rapid
activation of ARF which is ‘switched off’ downstream of
p19ARF activation after 72 h of induction and a DNA damage
response pathway keeping a low level of transcriptionally
active P53 sufficient to deal with a physiological elevation of
oxidative DNA injury. A possible connection between the
two pathways is discussed. 
Introduction
The retinoblastoma protein pRb is a critical regulator of cellular
proliferation. It forms a complex with E2F transcription
factors and inhibits their transcriptional activity. Upon phos-
phorylation by cyclin D-cdk4/6 in early G1 and cyclin E-cdk2
in late G1, pRb dissociates from the complex allowing E2F
to activate expression of genes required for S phase. pRb is a
tumor suppressor, and decreased expression is common in
cancer. 
Using a Cre/Lox system to specifically delete the Rb gene
from adult mouse hepatocytes by infection with an adenovirus
expressing the Cre recombinase (1,2), we are studying the
early effects of the loss of Rb. We have previously shown
in vitro that Rb deletion from primary liver cells quickly
leads to dysregulated proliferation, with the concomitant
appearance of multinucleated cells, cells with nuclei of
abnormal morphology or cells showing abnormal mitosis
reminiscent of abnormalities observed after Á-irradiation (1).
Interestingly, we have also reported that in response to Rb
deletion, P53 is rapidly stabilised and activated (2). However,
this stabilisation is only transient and resolves within 4 days
in culture. 
P53 regulates signalling pathways controlling cell pro-
liferation, apoptosis and DNA repair. Cellular P53 levels are
normally low due to rapid degradation by the proteosome,
promoted by the ubiquitin ligase and P53 partner MDM2.
In response to various stimuli, the interaction of P53 with
MDM2 is reduced through mechanisms ranging from post-
translational modification of either protein to protein/protein
interaction preventing the formation of MDM2/P53 complex
(reviewed in ref. 3), thus leading to P53 stabilisation and
accumulation.
In response to DNA injury, for example, various pathways
are activated depending on the nature of the DNA damage
and the cell type. However, all activate specific kinases
that are responsible for the phosphorylation of P53 at key
residues including Ser18 (Ser15 in human) (reviewed in
refs. 3-6). This phosphorylation is thought to disrupt the
interaction with MDM2, contribute to nuclear retention
and to activate P53. The same kinases also phosphorylate
other target proteins important for the regulation of cellular
responses to DNA damage, which can be used as markers
of DNA injury. One such marker is H2Ax, a Histone2A
variant that rapidly undergoes phosphorylation on Ser139
(ÁH2Ax) in response to DNA damage, particularly double
strand breaks (7-9). 
P53 can also be stabilised in response to aberrant activation
of oncogenes (10), including E2F1, in which case instability
arises from activation of the ARF pathway (p14ARF in human,
p19ARF in mouse). ARF is a nucleolar protein which can
sequester MDM2 (11-13), preventing its association with
P53 and restricting its E3 ligase activity (14,15). In this
instance P53 is stabilised without requiring phosphorylation.
One of the critical effects of Rb deletion is to increase
E2F activity (2,16). It has been reported that overexpression
INTERNATIONAL JOURNAL OF ONCOLOGY  37:  31-39,  2010 31
Independent regulation of P53 stabilisation and activation 
after Rb deletion in primary epithelial cells
LOUISE TREANOR,  CHRISTOPHER BELLAMY,  DAVID J. HARRISON  and SANDRINE PROST
Division of Pathology, Queen's Medical Research Institute, 49 Little France Crescent, Edinburgh, EH16 4TJ Scotland, UK
Received January 21, 2010;  Accepted March 16, 2010
DOI: 10.3892/ijo_00000650
_________________________________________
Correspondence to: Dr Louise Treanor, Present address:
Department of Hematology, St. Jude Children's Research Hospital,
Memphis, TN 38105 , USA
E-mail: louise.treanor@stjude.org
Key words: ARF, Rb, cre/lox, oxidative injury, hepatocytes
31-39.qxd  21/5/2010  12:13 ÌÌ  ™ÂÏ›‰·31
of E2F activates p19ARF (17). With this in mind, we asked
what pathway(s) activated after Rb deletion from otherwise
genetically normal primary epithelial cells might account for
the rapid but transient stabilisation of P53. 
Materials and methods
Hepatocyte isolation, culture and adenovirus infection. Mouse
primary hepatocytes (male, 6-12 weeks old), were isolated by
a two-step retrograde liver perfusion (18) of Rb-floxed mice
(19) and plated onto fibronectin-coated plastic in serum-free
medium supplemented as previously described (1).
Wild-type and Rb-/- isogenic hepatocytes were obtained
by infection of the hepatocytes in vitro with an adenovirus
expressing Cre-recombinase under the human CMV promoter
(Ad-Cre) or an adenovirus control (Ad-Dl70) (Virapur, USA)
a multiplicity of infection of 10 (2,20). Both adenoviruses are
replication-deficient (E1 deleted) serotype 5. Infection with
the adenovirus expressing Cre-recombinase leads to deletion
of the Rb gene within 16-24 h while cells infected by the
adenovirus control are phenotypically wild-type.
Immunoblotting. Proteins were prepared from snap-frozen
cell pellets using the appropriate lysis buffer. H2A.X, 10 mM
HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl. All other
proteins, 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA,
2.5 mM EGTA, 0.1% Tween-20.
Proteins were separated on SDS-PAGE and detected
with a rabbit polyclonal to p19ARF (Ab-80 Abcam, UK), ATR
(Ab10312 Abcam), ß-actin (Ab8227, Abcam), p53 (CM5,
kind gift from Professor T. Hupp) phospho-p53 (9284, Cell
Signalling, UK), P21 (M7202, Dako, UK) Chk1 (2345 Cell
Signalling), phospho-Chk1 (2344 Cell Signalling), Chk2 (2662,
Cell Signalling), NPM (15440, Abcam), mouse monoclonal
to H2A.X (JBW301 Upstate, UK), MDM2 (clones 2A10
and 4B11 Calbiochem UK), sheep polyclonal to MnSOD
(574596 Calbiochem), diluted in 5% Marvel TBST or TBST
alone for p19ARF and the appropriate secondary antibodies.
Proteins were visualized by ECL-plus using a versadoc4000
(Bio-Rad) to capture images and Versadoc Imaging for densito-
metric analysis.
Immunoprecipitation. Immunoprecipitation was performed
from 400 μg of protein using TrueBlot™ (eBioscience)
according to the manufacturer's instructions. Negative controls
were protein A incubated with the cell lysate without antibodies.
Immunofluorescence. Hepatocytes were fixed in acetone/
methanol (1:1 v/v). Immunodetection was performed using
anti-P21 (mouse monoclonal M7202, Dako), anti-nucleolin
(rabbit polyclonal Ab16940, Abcam) (1:100), anti-ATR
(Ab10312 Abcam), mouse monoclonal anti-H2A.X (1:100)
(05-636 Upstate), mouse monoclonal anti-p53 (clone pAb421,
Calbiochem), anti-MDM2 (clone 2A10, Calbiochem) and
rabbit polyclonal anti-p19ARF (1/20) (Ab-80, Abcam) and
the appropriate AlexaFluor secondary antibodies (Molecular
Probes, UK) followed by Topro-3 nuclear counterstain.
Detection of P19ARF required an avidin-biotin amplification
step (Sigma, UK). Where appropriate, quantification was
performed by manual counting on 25 representative fields (x40)
photographed with a Zeiss confocal microscope (LM510).
Scanning was performed using multitracking, and settings
constant throughout the experiments. Colocalisation studies
were performed using Bitplane Sofware on confocal images
taken with Nyquist oversampling, deconvoluted (21) using
Huygens Pro 5 software (Scientific Volume Imaging).
RT-PCR. Total RNA was extracted using Qiagen RNeasy
mini-column (Cat. no. 74104). cDNA was synthesised using
standard protocol with MMLV (Qiagen) reverse trans-
criptase and an Oligo-dT primer. For real-time RT-PCR, we
used Applied Biosystems ‘assay by design’ for E2F1
(Mm00432939_m1), GapdH (Mm99999915_q1) and custom
made for p19 ARF with the following primers and probe:
forward GGGCCGCACCGGAAT; reverse AAGAGCTGCT
ACGTGAACGT; FAM probe CCTGGACCAGGTGATGAT.
The reactions were run on an ABI PRISM 7900 Sequence
Detection System (AME Bioscience). 
For conventional RT-PCR, we used the following primers
and annealing temperatures: ARF: forward AGGGATCCTT
GGTCACTGTGAGGATTC, reverse GCAAAGCTTGAGG
CCGGATTTAGCTCTGCTC at 65˚C; ß-actin forward TTCT
TTGCAGCTCCTTCGTTGCCG, reverse TGGATGGCTGC
GTACATGGCTGGG at 60˚C.
ROS and DNA damage quantification
8-oxo-dG. DNA was extracted using sodium iodide method
(40) according to the manufacturer's recommendation (DNA
Extractor WB-Kit, Wako Pure Chemical Industries, Japan).
Briefly cells were lysed in a non-ionic surfactant, poly-
oxyethylene oxyphenyl ether buffer and spun at 10,000 g for
20 sec at 4˚C. The pellet was suspended in a SDS containing
protease solution for 1 h at 37˚C. After addition of NAI the
DNA was precipitated by addition of 0.5 ml of isopropyl
alcohol and resuspended in water. The levels of 8-oxo-dG were
measured using an ELISA kit according to the manufacturer's
instructions (JaICA, Japan) in control and Rb-/- DNA or 8-oxo-
dG standards.
AP site. Apurinic and apyrimindinic sites (AP sites) in
hepatocyte DNA were detected using a DNA damage
quantification kit according to the manufacturer's recom-
mendation (K253-25 Biovision, UK). Briefly, the extracted
DNA is incubated with a probe reacting with the aldehyde
groups in the AP sites in the DNA, leading to the tagging
with biotin residues which are detected with a colorimetric
assay. 
Reactive oxygen species (ROS). Measurement of ROS was
done using 5-(&6)-chloromethyl-2',7'-dichlorodihydro-
fluorescein diacetate (CM-H2DCFDA). CM-H2DCFDA is
a diacetate ester that enters passively into cells where it is
cleaved by intracellular esterases leading to its retention in
the cells. Reaction with intracellular ROS (hydrogen peroxide,
hydroxyl radical, peroxyl radical and peroxynitrite anion) leads
to emission of green fluorescence. The cells were treated
with 10 μM CM-H2DCFDA and fluorescence quantified
over one hour using a fluorimeter (Fluoroskan, Thermo Life
Sciences) at 485 nm and 510 nm with readings taken every
3 min. This was normalised according to the amount of protein
in each sample.
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Superoxide anion. Dihydroethidium (DHE) was used to
measure the amount of superoxide anion in the hepatocytes.
Upon reaction with ROS DHE is oxidised to ethidium that
intercalates into the DNA and fluorescence red. Cells were
incubated with DEH for 4 h, at 37˚C. Red fluorescence
(567 nm) was quantified as above.
Statistical analyses. Statistical analyses were performed
using Minitab 13.1 software. Effects of time and genotypes
were evaluated by univariate analysis of variance (ANOVA).
Differences were taken to be significant when p<0.05. Satis-
factory homogeneity of variances was determined with
Bartlett's test. Where a significant difference between means
was identified, we performed pairwise comparison of means
to the control using a Bonferroni correction for multiple
comparisons.
Results
We have previously shown that after Rb deletion p53 is
rapidly stabilised and that P21 expression is induced in a
p53-dependent manner (2): 72 h after infection of primary
RB-floxed hepatocytes with an adenovirus expressing the
Cre recombinase, 70-80% of the cells show strong p53 and
p21 nuclear positivity (2) (Fig. 1).
However, we also observed that the nuclear p53
stabilisation is only transient with the proportion of cells
showing nuclear positivity decreasing sharply 80-96 h after
infection (Fig. 1A). In contrast, P21 remains high and this
activation is P53-dependent (Fig. 1B).
After Rb deletion, a DNA damage pathway is activated. A
hallmark of P53 activation by DNA damage is phosphorylation
of Ser18 (Ser15 in human). This phosphorylation was detected
in Rb-/- cells only from 48 h after Rb deletion (Fig. 2). Further
evidence to support activation of DNA damage pathways was
the detection of increasing levels of ÁH2AX (phosphorylated
at Ser139), a recognised marker of DNA damage, in Rb-/-
cells: 96 h after Rb deletion 98-99% of Rb-/- cells were positive
for ÁH2AX (Fig. 2). Both P53 and ÁH2AX are components
of two DNA damage pathways that are driven by the DNA
damage kinases ATR and ATM via checkpoint kinases 1 and 2
(Chk1 and Chk2) respectively. However, neither changes in
ATM expression, nor phosphorylation of Chk2 on thr68 (target
site for ATM) were detected (data not shown), suggesting
that the ATM pathway is not involved here. By contrast, from
72 h after plating, ATR was found to localise in the nucleoli
of 50-80% of Rb-/- hepatocytes (Fig. 3), suggesting activation
of the protein (22). Phosphorylation of Chk1 kinase on
Ser317, a site targeted by ATR was also detected in Rb-/- cells
from 72 h, and could be inhibited by the addition of caffeine
[at a concentration of 2 mM, sufficient to inhibit the activity
of ATM and ATR but not DNA-PK (23)] (Fig. 3B and C).
Caffeine similarly inhibited the phosphorylation of P53 at
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Figure 1. P53 stabilisation is transient while P21 expression remains high.
(A) Immunofluorescence for P53 and P21 at indicated times after plating in
Rb-/- and wild-type hepatocytes. Ninety-six hours after plating the number of
P53 positive hepatocytes in Rb-/- decreases while >90% of the cells remains
P21 positive. (B) p21 expression is P53-dependent. Western blotting for
p21 at indicated times after plating in Rb-/- and wild-type hepatocytes, either
wild-type or p53-/-. In Rb-/- P21 is activated in a p53-dependent manner (50).
The level of P21 remains high 96 and 120 h after plating, times at which
P53 is no longer stabilised.
Figure 2. DNA damage markers are activated in Rb-/- hepatocytes. (A) Western
blotting for Ser18 phosphorylation of P53 and H2AX in Rb-/- and control
(wt) cells at indicated times after plating. ß-actin is shown as loading control.
The experiment was repeated with consistent results. (B) ÁH2AX immuno-
fluorescence. Photos show ÁH2AX immunofluorescence (green) 72 and 96 h
after plating in Rb-/- and control (wt). TO-PRO3 is a nuclear counterstain
shown here in blue. 
31-39.qxd  21/5/2010  12:13 ÌÌ  ™ÂÏ›‰·33
Ser18 (Fig. 3B and C) and reduced ÁH2AX phosphorylation
in Rb-/- cells (Fig. 3C). 
Both E2F1 (24) and ATR activation of Chk1 kinase can
inhibit NF-κB (22,25) which itself is an activator of the pro-
duction of MnSOD (26) a mitochondrial enzyme catalysing
superoxide anion turnover (27). We hypothetised that in Rb-/-
cells the activation of E2F (2) could indirectly lead to the
reduction of MnSOD expression and increased ROS leading
to DNA damage and activation of the DNA damage response
observed.
MnSOD protein was indeed detected 72 and 96 h after
plating in control but not Rb-/- cells (Fig. 4). This is consistent
with the activation of Chk1 (Fig. 3B) in Rb-/- cells indicating
that there may be inhibition of MnSOD (SOD2) expression
through ATR/Chk1 inhibition of the NF-κB, although this was
not investigated in more detail. We then asked whether the
decrease in MnSOD protein was sufficient to affect the level
of endogenous ROS, with consequences for DNA damage
and the observed activation of DNA damage pathways. 
First, we quantified ROS using two different compounds
(Fig. 5A  and B). From 48 h in culture ROS levels were consis-
tently greater in Rb-/- cells compared with wild-type control
(Fig. 5A) (Student's t-test p=0.03621). The same trend was
observed using DHE which detected higher levels of super-
oxide anion in Rb-/- hepatocytes compared to wild-type controls
(Fig. 5B) (asterisk denotes a significant difference using a
two-tailed t-test).
We then quantified 2 types of DNA injury known to arise
from ROS: 8-oxo-dG produced through the oxidation of
guanine and secondly, AP sites formed via hydrolysis of the
N-glycosyl bond. From 72 h in culture, the level of 8-oxo-dG
rose and was greater in Rb-/- compared with control hepatocytes
(Fig. 5C) (asterisk denotes a significant difference using a
two-tailed t-test). This increase was also observed for AP sites,
although statistical significance was not achieved (Fig. 5D,
p=0.1773) which could be expected as levels of endogenously
produced ROS levels are low and changes small.
Our results therefore support the hypothesis that in response
to Rb deletion, MnSOD expression is inhibited leading to
an increase in endogenous ROS with consequences for DNA
damage and activation of P53. However, while the DNA
damage pathway is still active 96 h after plating (H2AX
activated, P53 phosphorylated on Ser18, P53-dependent
activation of P21 expression, increased ROS and DNA
damage); the number of hepatocytes showing P53 stabilisation
decreased sharply (Figs. 1 and 6) to ~10%. This suggests
that the activation of the DNA damage pathway by a low
level of endogenous DNA injury, including phosphorylation
of P53 on Ser18 is not sufficient to maintain high levels of
P53 stabilisation. Indeed some Rb-/- hepatocytes positive
for ÁH2AX were negative for p53 (data not shown). We
investigated whether p19ARF could be involved. 
After Rb deletion, P19ARF is activated and contributes to P53
stabilisation. E2F overexpression has been shown to induce
P19ARF expression, and interaction of ARF with MDM2
stabilises P53. We therefore investigated whether P19ARF
was activated in response to Rb deletion.
P19arf expression was higher in Rb-/- cells compared with
control (Fig. 7). It was detected from 72 h in culture by RT
PCR (Fig. 7A) and from 48 h by Western blotting (Fig. 7B)
in Rb-/- cells. By contrast, there was no expression detectable
in control cells at early time-points and only weak expression
was observed 96 h after plating. Real-time PCR confirmed an
increase of ~10-fold of p19arf expression in Rb-/- cells (Fig. 7C),
and this was reduced when the cells were treated with E2F
antisense (Fig. 7D). 
Currently there is not one unifying model able to accurately
describe the regulation of p53 by ARF in the different systems
TREANOR et al:  ARF AND P53 REGULATION UPON LOSS OF THE Rb GENE34
Figure 3. The ATR/Chk1 kinase pathway is activated in Rb-/- cells. (A)
Immunofluorescence for ATR (green) at 48 and 72 h after plating. The
blue nuclear counterstain is TO-PRO3. From 72 h after plating Rb-/- cells
exhibited nucleolar staining of ATR (a). (B) Western blotting for Chk1,
Ser317 phosphorylation of Chk1 and Ser18 phosphorylation of P53 in
control (wt) and Rb-/- cells at indicated times after plating in the presence (+)
or absence (-) of caffeine. ß-actin is shown as loading control. The experiments
were repeated with consistent results. (C) Immunofluorescence for ÁH2AX
in control (wt) and Rb-/- cells 72 h after plating in the presence (+) or absence
(-) of caffeine. 
Figure 4. Inhibition of MnSOD expression in Rb-/- cells. Western blotting for
MnSOD in control (wt) and Rb-/- cells at indicated times after plating.
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studied. It is clear that ARF stabilises P53 through binding
to MDM2, thus preventing the formation of MDM2/p53
complexes and targeting of P53 for degradation but the
regulation of ARF itself seems to be different in different
systems. ARF localisation and its interaction with the nucleolar
protein NPM/B23 are nevertheless central to the problem and
were studied next. 
There were no significant differences between MDM2
protein levels detected in control and Rb-/- cells (data not
shown). P19ARF immunoprecipitation pulled down MDM2
in Rb-/- cells only (Fig. 8) confirming an interaction between
these proteins 48 and 72 h after plating. The interaction was
greatly decreased 96 h after plating, in agreement with the
decreased P53 nuclear staining observed at that time (Fig. 6). 
According to some models, ARF localisation is thought to
affect its ability to stabilise p53. P19ARF was detected in Rb-/-
cells only (Fig. 9A) and localised in the nucleoli at all time-
points as confirmed by co-staining with nucleolin (Fig. 9B).
Quantification showed that the number of Rb-/- cells positive
for P19ARF rose sharply, following the increased of P53
positive cells but remained high after 72 h when the number
of P53 positive cells decreases (Fig. 9C). Thus the interaction
between P19ARF with MDM2 did correlate closely with
P53 stabilisation but was not regulated by a change in the
localisation of P19ARF.
Nucleophosmin (NPM), a nucleolar phosphoprotein, can
compete with MDM2 for interaction with P19ARF (28). We
investigated if NPM was involved in the changes of interaction
between MDM2 and P19ARF. Wild-type and Rb-/- hepatocytes
showed similar NPM expression patterns (Fig. 10A), but
immunoprecipitation with P19ARF antibodies pulled down
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Figure 5. Reactive oxygen species (ROS) and DNA damage increase in Rb-/- cells. Quantification of the levels of ROS using CM-H2DCFDA (A) and DHE (B).
In both cases, control and Rb-/- hepatocytes (white and black bars, respectively) were incubated with the compound as described in Materials and methods. The
fluorescence was quantified and normalised for the amount of protein per sample. Both assays were done in triplicate and repeated three times with consistent
results. Quantification of the levels of 8-oxo-dG (C) and AP sites (D) in wt and Rb-/- hepatocytes (white and black bars, respectively). Standard curves of
known concentrations of 8-oxo-dG and AP sites were used for the calculations. Both assays were performed in triplicate and repeated twice with consistent
results. *Statistically significant difference (see text).
Figure 6. Quantification of P53 positive Rb-/- cells. The proportion of Rb-/-
hepatocytes positive for P53 were counted at the indicated times. Five  hundred
cells were counted in duplicate. The values are mean ± SD.
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NPM in Rb-/- only, showing an interaction between the two
proteins from 72 h after plating (Fig. 10B).
Discussion
Oncogenic stimuli leading to P53 stabilisation are complex
as they can potentially trigger multiple apparently unrelated
pathways. An example is shown here using primary epithelial
cells, where a physiological increase in E2F activity is obtained
in response to acute Rb deletion. On one hand, increased
E2F activity activates the expression of ARF which interacts
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Figure 7. p19arf expression is increased in Rb-/- cells and depends on increased E2F activity. (A) RTPCR for p19arf and ß-actin in control (wt) and Rb-/- cells in
culture for the indicated times. (B) Western blotting for P19ARF and ß-actin in control (wt) and Rb-/- cells in culture for the indicated times. (C) Real-time PCR
for p19arf expression corrected for GAPDH expression. (D) Real-time PCR for E2F and p19arf expression corrected for GAPDH expression in control and
Rb-/- cells in culture for 72 h, treated with E2F antisense for 30 h. The results for E2F expression after treatment with antisense has already been published by
the authors (16). (C and D) White bars, control; black bars, Rb-/- hepatocytes.
Figure 8. P19ARF interacts with MDM2 in Rb-/- cells. Proteins isolated from
control (wt) and Rb-/- samples at indicated times were immunoprecipitation
with an antibody to p19ARF. The precipitates were immunoblotted for
MDM2 using to 2 different antibodies Ab2 (2A10) and Ab3 (4B11) which
recognize different regions of the protein. 
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with MDM2 and contributes to P53 stabilisation. On the
other hand, E2F leads to decreased MnSOD expression,
accumulation of reactive oxygen species and DNA damage,
triggering a DNA injury response that can activate P53 through
post-translational modifications including phosphorylation
of Ser18. While the DNA damage response is sustained, the
stabilisation of P53 resolves within 96 h showing that the two
pathways are regulated independently. 
Rb deletion leads to DNA injury. Based on our data and
others we suggest the following model: upon Rb deletion,
E2F activation leads to Arf induction, ATM/Chk1 activation
which can inhibit relA (NF-κB) (22). This relA inhibition
leads to decreased MnSOD (SOD2) expression resulting in
accumulation of endogenous ROS leading to DNA injury
and activation of DNA damage pathways: activation of
ATR/chk1, ÁH2AX and phosphorylation of P53. Interestingly,
others have also observed activation of ÁH2AX in response to
Rb deletion (29,30). However, these studies clearly suggest
that ÁH2AX is not associated with ROS induced DNA damage
(30) but rather with DSB induced at the replication fork
(29). Although in some cases activation of ATM/chk2 or
ATR/chk1 are clearly associated with a specific type of DNA
injury, often the situation is more complex with simultaneous
activation and/or interconnection of the two pathways.
Pickering and Kowalik found that ÁH2AX induction in
response to Rb deletion was ATM-independent supporting
our result (30). By contrast in response to TWIST depletion,
which activates ARF, ÁH2AX increases together with acti-
vation of both chk1 and chk2 kinases (31). This suggests
that activation of ÁH2AX in response to Rb deletion and/or
ARF over-expression may result from a combination of DNA
damage pathways that may be cell type specific. In summary,
the increased ROS and ÁH2AX activation clearly shows that
Rb loss leads to DNA injury and P53 stabilisation. In fact this
could be contributing to the early activation of DNA damage
checkpoints observed in early human carcinogenesis (32).
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Figure 9. ARF localised in the nucleoli. (A) Immunofluorescence for P19ARF in control (wt) and Rb-/- cells 48, 72 and 96 h after plating. Green fluorescence,
P19ARF; blue fluorescence, nuclear counterstain with TO-PRO3. (B) Double immunofluorescence for P19ARF and nucleolin in control (wt) and Rb-/- cells,
72 h after plating. Red fluorescence, P19ARF; green fluorescence, nucleolin; blue fluorescence, nuclear counterstain with TO-PRO3. (C) Graph showing
the quantification of P53 and ARF positive Rb-/- cells at indicated time. Note that the number of cells positive for ARF remains high while the number of P53
positive cells decreases after 78 h.
Figure 10. NPM is expressed in hepatocytes and interacts with P19ARF in
Rb-/- cells 96 h after plating. (A) NPM expression in control (wt) and Rb-/-
hepatocytes at indicated times after plating. (B) Immunoprecipitation with
P19ARF antibodies. Control (wt) and Rb-/- proteins were immunoprecipitated
with an antibody against p19ARF and probed with an antibody against NPM
at indicated times after plating.
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Arf-dependent regulation of P53 stabilisation. Interestingly, we
observed a dynamic regulation of P53 with rapid but transient
stabilisation, then return to low protein levels, which was
correlated with ARF-MDM2 interaction. The currently
favoured model of regulation of P53 by ARF suggests that in
the nucleoli, ARF is sequestered by NPM and unable to interact
with MDM2. In that model, in response to high levels of DNA
injury, ARF relocalises to the nucleoplasm where it binds to
MDM2, leading to P53 stabilisation (reviewed in refs. 33,34). 
In the present system, where gene expressions are endo-
genous, we confirm that ARF interaction with MDM2 dictates
the level of P53 protein and that interaction between ARF
and MDM2 is abolished by NPM binding to ARF. However
this change in interaction occurs without dissociation of
the nucleoli or relocalisation of ARF. Brady et al (28) have
recently demonstrated that ARF/NPM and ARF/MDM2
are independent protein complexes. Interestingly, they also
demonstrated a binding preference of ARF for MDM2 over
NPM suggesting that an active regulation must take place for
the binding to change from MDM2 to NPM. NPM has been
shown to be induced by exogenous DNA damage (35,36) and
a difference in the stoichiometry between MDM2 and NPM
could be sufficient to affect the binding partner (28,34), even
in absence of damage to the nucleoli structure. However, we
did not observe a change in NPM protein level suggesting
that another mechanism is involved for the observed regulation
of ARF binding to MDM2. We have observed in Rb-/- cells
homodimeric forms of P19ARF at the time of decreased
interaction with MDM2 (data not shown). ROS have been
shown to induce homodimerisation of the human form of
P19ARF (P14ARF) which leads to a decreased affinity for
HDM2 (37). Based on this work in human cells and our own
work, we postulate that in response to Rb deletion, increased
endogenous ROS may promote homodimerisation of P19ARF
at late time-points leading to a decrease affinity for MDM2.
NPM can bind to ARF leading to a return to MDM2-dependent
degradation of P53.
Feed-back loops and interaction of two pathways. P53 is
critical in the regulation of many cellular responses and
(the) many ways by which P53 activity can be regulated are
now clearly established. However, as discussed by Harris and
Levine, the regulatory mechanisms have often been studied
in established, frequently transformed cell lines, which are
likely to bear various mutations, using overexpression vectors,
mutant proteins and/or high levels of DNA damage (38).
The many feed-back loops that exist are likely to provide a
different picture in a physiological system. 
Using primary epithelial cells, in which Rb is deleted
acutely, we have shown how deletion of Rb can trigger 2
pathways of activation of P53 which may be interconnected
but are regulated independently: P53 remains transcriptionally
active at times when NPM interacts with ARF and the overall
P53 protein level has returned to baseline. This suggests
that P53 stabilisation and activation are independent in this
setting as previously suggested by others (39). ARF has been
reported to promote some post-translational modifications
liable to activate P53 such as acetylation (40,41) or ATM
dependent phosphorylation on Ser15 (42), however, these
modifications can also be activated by DNA damage path-
ways whose activation was not ruled out in those studies. By
contrast P53 can be stabilised without phosphorylation on
Ser15 (43) supporting our hypothesis that arf overexpression
stabilises P53 but activation itself results from another
pathway, activation of ATR/Chk1pathway by ROS-induced
DNA damage.
This regulation may provide a mechanism where the
cells are able to sense the level of stress and prevent P53
stabilisation, possibly until the stress is such that elimination
of the cells is necessary (44). The role of P53 in controlling
apoptosis needs indeed to be tightly controlled to allow its
activity in regulating other critical cellular pathways such as
proliferation and differentiation.
This is supported by work suggesting that interaction
between NPM and ARF has a regulatory role by promoting
the accumulation of inactive ARF until it is required, and
thus could set a threshold for P53 response (45,46). In the
presence of high level of DNA injury, such as in studies
involving UV-induced DNA damage (47) NPM can repress
P53 activation until the levels of damage are such that DNA
repair pathways or apoptosis should be activated (46,47). In this
case the high level of DNA damage promotes a redistribution
of ARF; NPM/ARF complexes disappear from the nucleoli and
ARF complexes with MDM2 in the nuclei (47) although this
may be due to damage to the nucleoli itself rather than to the
DNA (48). A recent study further suggests that redistribution
of ARF may be limited to DNA damage that induces the JNK
pathway (49). In the absence of JNK induction, as observed
after ionising radiation (49), ARF could be activated without
relocalisation as observed in the present study. 
In conclusion, the present data from primary cells suggests
that the mdm2/p53/NPM/ARF pathway provides a patho-
physiologic sensor mechanism allowing inhibition of
proliferation by low levels of active P53, perhaps giving the
opportunity for DNA repair to occur, while apoptosis is
inhibited. In normal cells, a low level of ROS and DNA
damage activates sufficient P53 to induce P21 and lead to cell
cycle arrest. However, the overall amount of P53 protein would
be kept low as NPM interacts with ARF and P53 is targeted to
degradation by MDM2. Additional signal, such as high levels
of damage could activate ARF and stabilisation of P53 would
allow induction of apoptosis. This mechanism allows to
maintain P53 below the threshold necessary for cell death (44).
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